Full phase 3 data from EASD and The Lancet: 1,152 adults, three doses over 80 weeks, A1C down about 1.5 points, with diarrhea and nausea the top side effects.
Recap by typeshit. Full story at Drug Topics.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
Robert Lufkin MD shares the observational data: an average 16.1 kg lost at six months among 7,297 women, with 62.7% reporting side effects.
The Medlines hosts go over trial data showing average weight loss of up to 28.3% at 80 weeks, alongside other medical news of the day.
Lilly is moving against sellers of copycat versions of its unapproved triple agonist, the latest step in the push against gray market retatrutide.
Loading…